<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1286">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341870</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200375-3</org_study_id>
    <nct_id>NCT04341870</nct_id>
  </id_info>
  <brief_title>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</brief_title>
  <acronym>CORIMUNO-VIRO</acronym>
  <official_title>Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to determine the therapeutic effect and tolerance of
      Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab
      only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019
      (COVID-19). Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both
      soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit
      IL-6-mediated signaling through these receptors. The study has a cohort multiple Randomized
      Controlled Trials (cmRCT) design. Randomization will occur prior to offering investigational
      treatments administration to patients enrolled in the CORIMUNO-19 cohort (NCT04324047).
      Sarilumab+Azithromycin+Hydroxychloroquine, or Sarilumab only will be administered to
      consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe
      pneumonia requiring no mechanical ventilation. All patients will receive standard of care
      along with randomized investigational treatments. Outcomes of included patients will be
      compared between groups as well as with outcomes of patients in the CORIMUNO-19 cohort
      treated with other immune modulators or standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    DSMB recommendation (futility)
  </why_stopped>
  <start_date type="Actual">April 11, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bayesian open labelled randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for ventilation (including invasive and non invasive ventilation), intensive care or death</measure>
    <time_frame>14 days</time_frame>
    <description>Events considered are: need for ventilation (including invasive and non invasive ventilation), transfer to the Intensive Care Unit, death or new do-not-resuscitate (DNR) decision in the absence ventilation and outside ICU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early improvement: OMS progression scale &lt;= 5</measure>
    <time_frame>4 days</time_frame>
    <description>WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2&gt;=150 OR SpO2/FIO2&gt;=200: 7 Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMS progression scale</measure>
    <time_frame>4, 7 and 14 days</time_frame>
    <description>WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2&gt;=150 OR SpO2/FIO2&gt;=200: 7 Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>14, 28 and 90 days</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days alive</measure>
    <time_frame>14, 28 and 90 days</time_frame>
    <description>Number of ICU-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation-free days alive</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Number of ventilation(invasive or non invasive)-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days alive</measure>
    <time_frame>14, 28 and 90 days</time_frame>
    <description>Number of hospital-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy-free days alive</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Number of oxygen therapy-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative viral excretion</measure>
    <time_frame>90 days</time_frame>
    <description>SARS-CoV-2 viral load measurement by rtPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping and multiplex cytokines</measure>
    <time_frame>8 days</time_frame>
    <description>Immunophenotyping and multiplex cytokines (blood sample)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>COVID19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab combined with Azithromycin and Hydroxychloroquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sarilumab only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1</description>
    <arm_group_label>Sarilumab</arm_group_label>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)</description>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)</description>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients included in the CORIMUNO-19 cohort (NCT04324047)

          -  COVID-19 cases not requiring ICU at admission with moderate or severe pneumopathy
             according to the WHO Criteria of severity of COVID pneumopathy:

               -  Moderate cases: Cases meeting all of the following criteria: [Showing fever and
                  respiratory symptoms with radiological findings of pneumonia] AND [Requiring
                  between 3L/min and 5L/min of oxygen to maintain SpO2&gt;97%] OR

               -  Severe cases: Cases meeting any of the following criteria: [Respiratory distress
                  ( ≥ 30 breaths/ min)] OR [Oxygen saturation≤93% at rest in ambient air; or Oxygen
                  saturation ≤97 % with O2 &gt; 5L/min] OR [PaO2/FiO2 ≤ 300mmHg]

        Exclusion Criteria:

          1. Patients with exclusion criteria to the CORIMUNO-19 cohort.

          2. Respiratory failure requiring non invasive or mechanical ventilation

          3. Patients requiring intensive care

          4. Do-not-resuscitate order (DNR order)

          5. Known hypersensitivity to sarilumab or to any of their excipients.

          6. Known contra-indication to hydroxychloroquine or chloroquine: including
             hypersensitivity/allergy, retinopathy, G6PD deficiency and QT prolongation

          7. Known contra-indication to azithromycin: including hypersensitivity/allergy and QT
             prolongation

          8. Pregnancy or breastfeeding

          9. Current documented bacterial infection.

         10. Patient with any of following laboratory results out of the ranges detailed below at
             screening should be discussed depending of the medication:

               -  Absolute neutrophil count (ANC) ≤ 1.0 x 109/L

               -  Haemoglobin level: no limitation

               -  Platelets (PLT) &lt; 50 G /L

               -  SGOT or SGPT &gt; 5N
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AP-HP Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

